Diem Nguyen - Dec 31, 2021 Form 5/A - restatement Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ John Canepa, Attorney-in-Fact
Stock symbol
CADL
Transactions as of
Dec 31, 2021
Transactions value $
$0
Form type
5/A - RESTATEMENT
Date filed
2/14/2022, 07:31 PM
Date Of Original Report
Feb 14, 2022
Previous filing
Aug 2, 2021
Next filing
Jun 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Stock Option (Right to Buy) Award $0 +28.5 K $0.00 28.5 K Jul 26, 2021 Common Stock 28.5 K $8.00 Direct F1

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in thirty-six equal monthly installments following July 26, 2021, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

This Form 5/A is being filed to correct the number of shares underlying options reported in Table II, Columns 5, 7 and 9.